The pharmacoeconomics of the new antiepileptic drugs

Epilepsia

Volumn 40, Issue SUPPL. 8, 1999, Pages 25-31

  Heaney, Dominic ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EPILEPSY; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTICONVULSANTS; COST CONTROL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DRUG COSTS; ECONOMICS, MEDICAL; ECONOMICS, PHARMACEUTICAL; EPILEPSY; HEALTH CARE COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 0032747662     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00944.x     Document Type: Review

References (36)

1. Sander JWAS, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996;61:433-43.
2. Marson AG, Kadir ZA, Chadwick DW. New anti-epileptic drugs: a systematic review of their efficacy and tolerability. Br Med J 1996;313:1169-74.
3. Association of the British Pharmaceutical Industry. Compendium of data sheets and summaries of product characteristics 1996-1997. London: ABPI, 1996:770.
4. Anonymous. Epilepsy: Prescription Pricing Authority Matters. London: UK Prescription Pricing Authority, 1998;27.
5. Ferner RE. Newly licensed drugs. Br Med J 1996;313:1157-8.
6. Mignot G. Drug trials in epilepsy. Br Med J 1996;313:1158.
7. Walker MC, Sander JWAS. Long term use of lamotrigine and vigabatrin in severe refractory epilepsy; audit of outcome. Br Med J 1996;313:1184-5.
8. Sander JWAS. New drugs for epilepsy. Curr Opin Neurol 1998; 11:141-8.
9. Brodie MJ, Richens A, Yuen AWC. A randomised open multicentre comparative trial of lamotrigine and carbamazepine. Lancet 1995;345:476-9.
10. Drummond MF, Stoddart GL, Torrance GW, eds. Methods for the economic evaluation of healthcare programmes. Oxford: Oxford University Press, 1986.
11. McGuire A, Henderson J, Mooney G, eds. The economics of health care. London: Routledge, 1995.
12. Banks GK, Regan KJ, Beran RG, Pachlatko C, eds. Cost of epilepsy: the prevalence and direct and indirect costs of epilepsy in Australia. Ciba Geigy Verlag, 1993:39-54.
13. Cockerell OC, Hart YM, Sander JWAS, Shorvon SD. The cost of epilepsy in the United Kingdom; an estimation based on the results of two population-based studies. Epilepsy Res 1994;18:249-60.
14. Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48.
15. Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994;35:1230-43.
16. Gessner U, Sagmeister M, Horisberger B, Pachlatko C, Beran RG, eds. Cost of epilepsy: the economic impact of epilepsy in Switzerland. Ciba Verlag, 1993:67-74.
17. van Hout B, Gagnon D, Souetre E, Ried S, Remy C, Baker G, Genton P, Vespignani H, McNulty P. Relationship between seizure frequency and costs and quality of life of out-patients with partial epilepsy in France, Germany and the United Kingdom. Epilepsia 1997;38:1221-6.
18. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996;10:460-6.
19. Kobelt G, ed. Health economics: an introduction to economic evaluation. London: Office of Health Economics, 1996.
20. Fink A, Kosecoff J, Chassin M, Brook R. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984; 74:979-83.
21. O'Niell B, Trimble MR, Bloom DS. Adjunctive therapy in epilepsy: a cost-effectiveness comparison of alternative treatment options. Seizure 1995;4:37-44.
22. Johnson WG. The costs of epilepsy and cost-based evaluations of anticonvulsants. Pharmacoeconomics 1997;12:446-59.
23. Wiebe S, Gafni A, Blume WT, Girvin JP. An economic evaluation of surgery for temporal lobe epilepsy. J Epilepsy 1995;8:227-35.
24. Jackson D, Duthie T. If comparisons can be odious, so can assumptions [Letter]. Seizure 1996;5:247-8.
25. Heller AJ, Chesterman P, Elwes RDC, Crawford P, Chadwick D, Johnson AL, Reynolds TF. Phenobarbitone, phenytoin, carbamazepine or valproate for newly diagnosed adult. J Neurol Neurosurg Psychiatry 1995;58:44-50.
26. Callaghan N, Kenny RA, O'Niell B, Crowley M, Goggin T. A prospective study between carbamazepine, phenytoin and valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsy. J Neurol Neurosurg Psychiatry 1985;48: 639-44.
27. Ramsay RE, Wilder BJ, Berger JR, Bruni J. A double blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology 1983;33:904-10.
28. Turnbull DM, Howel D, Rawlins MD, Chadwick D. Which drug for the adult epileptic patient: phenytoin or valproate? Br Med J 1985;290:815-9.
29. Steiner TJ, Yuen AWC. Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy. Epilepsia 1994;35 (suppl 8):31.
30. Akyol A, Yoldas T, Baydas G, Mungen B. Lamotrigine versus valproate as monotherapy in patients with newly diagnosed epilepsy. Epilepsia 1998;39(suppl 2):23.
31. Heaney DC, Sander JWAS, Shorvon SD. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment for adults with newly diagnosed epilepsy. Epilepsia 1998;39(suppl 3):19-25.
32. Hughes D, Cockerell OC. A cost minimisation study comparing vigabatrin, lamotrigine, and gabapentin for the treatment of intractable epilepsy. Seizure 1996;5:89-95.
33. Messori A, Trippoli S, Becagli P, Concotta M, Labbate MG, Zaccara G. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol 1998;53:421-7.
34. Gillham R, Baker G, Thompson PJ, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side effects of anti-epileptic drug treatments. Epilepsy Res 1996;24:47-55.
35. Maynard A, Bloor K. Regulating the pharmaceutical industry. Br Med J 1997;315:200-1.
36. Earl-Slater A. Regulating the price of the UK's drugs: second thoughts after the government's first report. Br Med J 1997;314: 365-8.